Welcome to the era of mindful medicine.
Psilera delivers therapies designed to change the way the world thinks.
The Latest From The Lab:
Psilera welcomes
Scott W. Rairigh, M.S.
as
Executive Vice President of Corporate Development
Read the full press release here!
Psilera
At A
Glance
-
We have created and developed six separate serotonergic compound families.
-
Two patents have been issued from the USPTO covering over 1 million novel compounds. Several more patents expected by 1H 2024.
-
The Psilera leadership team has over 100 years of combined experience in the biotech and pharmaceutical industries.
-
Our best-in-class proprietary compound library has coverage for over 1 million novel compounds.
-
Psilera’s co-founders bring over $1.5B in cumulative value created from prior start-ups.
Psilera is revolutionizing how small molecule drug discovery is done, giving rise to more patient-centric therapy options for those suffering from neurological conditions.
Based on the current pipeline, our focus is on hard-to-treat disorders, many of which have no currently available treatments, such as Frontotemporal Dementia (FTD).
UPCOMING EVENTS
UPCOMING EVENTS
September 9 - 11
Boston, MA
November 13 - 14
Madison, WI
Neuropsychiatric Drug Development Summit
Jackie von Salm, PhD will be in Boston for the 8th Annual Neuropsychiatric Drug Development Summit. Dr. von Salm will be participating in two sessions. The first is a workshop on Day 1 discussing new strategies for using animal models to more accurately predict the effects of antidepressants, antipsychotics and anxiolytics in humans. The second is a seminar on Day 2, detailing in vitro and in vivo studies of PSIL-006’s mechanism of action and the potential it offers for treating the symptoms of neurodegeneration.
Psychedelic Symposium
Jackie von Salm, PhD will be in Wisconsin for the University of Wisconsin- Madison Psychedelic Symposium. She will be speaking about non-hallucinogenic derivatives of psychedelics for the treatment of mental health disorders and neurodegeneration. The Symposium is aimed at expanding awareness, fostering knowledge exchange, and bridging gaps in psychedelic research, education, and policy. If you would like to connect with Dr. von Salm while she is at the Symposium, please contact info@psilera.com to arrange a time.